Skip to main content

Table 4 Comparison of immunization effects on extrauterine prevention alone for newborns of HBsAg- and/or HBeAg-positive women &

From: Immunization interventions to interrupt hepatitis B virus mother-to-child transmission: a meta-analysis of randomized controlled trials

Pregnancy infection status Newborn infection status Detective time Number of included studies Sample size Meta-RR (95% CI)
Total (HBsAg+ and/or HBeAg+) HBsAg+ At birth 7 1061 0.66(0.52,0.84) 3)
7-12 month 12 1451 0.54(0.42,0.69) 3)
>12 month 7 1214 0.54(0.42,0.69) 3)
HBsAb+ At birth 4 291 2.12(1.66,2.70) 3)
7-12 month 8 566 1.12(1.03,1.22) 3)
>12 month 5 502 1.06(0.96,1.16)3)
Subgroup (HBsAg+ and HBeAg+) HBsAg+ At birth 7 782 0.75(0.57,0.99) 3)
7-12 month 12 1095 0.56(0.42,0.75) 3)
>12 month 7 889 0.55(0.41,0.75) 3)
HBsAb+ At birth 4 291 3.25(1.35,7.83) 2)
7-12 month 9 443 1.14(1.05,1.24) 3)
>12 month 5 502 1.06(0.96,1.16)3)
Subgroup (HBsAg+ and HBeAg-) HBsAg+ At birth 1 279 0.59(0.34,1.02)3)
7-12 month 3 356 0.64(0.39,1.06)3)
>12 month 2 325 0.63(0.41,0.97) 3)
Subgroup (low + unclear bias) HBsAg+ At birth 4 348 0.82(0.58,1.18)3)
7-12 month 10 739 0.56(0.38,0.82) 3)
>12 month 4 400 0.43(0.23,0.82) 3)
HBsAb+ At birth 3 221 4.21(2.70,6.57) 3)
7-12 month 8 566 1.12(1.03,1.22) 3)
>12 month 4 400 1.05(0.93,1.17)3)
Subgroup (high risk bias) HBsAg+ At birth 3 713 0.58(0.42,0.81) 3)
7-12 month 2 712 0.53(0.39,0.72) 3)
>12 month 3 814 0.56(0.43,0.73) 3)
HBsAb+ At birth 1 70 0.91(0.76,1.09)
7-12 month - - -
>12 month 1 102 1.09(0.93,1.27)
  1. &(Mother: none/Infants: HBIG + vaccine) vs (Mother: none/Infants: vaccine); 2)Random effects model, inverse variance method; 3)Fixed effects model, Mantel-Haenszel method; values in boldface indicate statistical significance (P < 0.05).
\